Phase III Data for Teva Pharmaceutical Industries Limited (TEVA)’s QNASL® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients With Seasonal Allergic Rhinitis  
11/9/2012 11:24:05 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. announced today additional data from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal Aerosol, highlighting the drug’s efficacy profile in treating children (ages 6-11) with nasal symptoms of seasonal allergic rhinitis (SAR). QNASL® is a nonaqueous, “dry” nasal aerosol corticosteroid currently approved for the treatment of nasal symptoms associated with SAR and perennial allergic rhinitis (PAR) in patients aged 12 years and older. The data are being presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA. Additional data also presented at the ACAAI meeting reinforce the long-term ocular safety profile of QNASL® and the functionality and reliability of the device.